The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Westlake and Ascend close plants, Chemify opens AI-robotics lab, Formation licenses gusacitinib to Sanofi, and more ...

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

NEW YORK, NY, USA I June 23, 2025 I Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has licensed gusacitinib, an ...

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its subsidiary Libertas Bio has licensed gusacitinib to Sanofi, expanding the ...

Sanofi will explore additional indications for gusacitinib in a Phase I study. Sanofi has licensed gusacitinib, an oral JAK/SYK dual inhibitor from the “AI-native” drug development company Formation ...

Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi, which will explore its potential in a new indication not previously studied through a ...